{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058376,"version":"4.3.4"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coi.2025.102658","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:40:29Z","timestamp":1758062429000},"page":"102658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advances in treatment of psoriatic arthritis: current guidelines and emerging therapies"],"prefix":"10.1016","volume":"97","author":[{"given":"Ashley M","family":"Feldkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102658_sbref1","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coi.2025.102658_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_sbref3","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1093\/rheumatology\/keae702","article-title":"Total-body positron emission tomography: a tool for systemic, quantitative evaluation of the inflammatory burden of psoriatic arthritis","volume":"64","author":"Raychaudhuri","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102658_bib4","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2025.102658_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheuma Oxf Engl"},{"key":"10.1016\/j.coi.2025.102658_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3899\/jrheum.190512","article-title":"Imaging techniques: options for the diagnosis and monitoring of treatment of enthesitis in psoriatic arthritis","volume":"47","author":"Bakewell","year":"2020","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_sbref7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.berh.2014.10.004","article-title":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","volume":"28","author":"Machado","year":"2014","journal-title":"Best Pr Res Clin Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221086710","article-title":"Psoriatic arthritis: prospects for the future","volume":"14","author":"Hackett","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.coi.2025.102658_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib10","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/acs.jproteome.5b00756","article-title":"A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins","volume":"14","author":"Hong","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.coi.2025.102658_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/1744666X.2016.1147954","article-title":"Biomarkers in psoriatic arthritis: a systematic literature review","volume":"12","author":"Generali","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib13","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3899\/jrheum.101117","article-title":"Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Chandran","year":"2011","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Brief Report: Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib19","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.181089","article-title":"Endorsement of the 66\/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report","volume":"46","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10067-014-2734-8","article-title":"Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis","volume":"34","author":"K\u0131l\u0131\u00e7","year":"2015","journal-title":"Clin Rheuma"},{"key":"10.1016\/j.coi.2025.102658_sbref22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_sbref23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheuma"},{"issue":"8","key":"10.1016\/j.coi.2025.102658_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.2024-0074","article-title":"Clinical validation of digitally acquired clinical data and machine learning models for remote measurement of psoriasis and psoriatic arthritis: a proof-of-concept study","volume":"51","author":"Webster","year":"2024","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib26","article-title":"Exacerbation of psoriasis with meclofenamate","volume":"309","author":"Meyerhoff","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib27","series-title":"StatPearls [Internet]","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","author":"Ghlichloo","year":"2024"},{"key":"10.1016\/j.coi.2025.102658_bib28","first-page":"S17","article-title":"The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide","volume":"19","author":"Sarzi-Puttini","year":"2001"},{"key":"10.1016\/j.coi.2025.102658_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semarthrit.2007.03.004","article-title":"A comparison of the efficacy and safety of Celecoxib 200 mg and Celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis","volume":"37","author":"Kivitz","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib30","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib31","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheuma Oxf Engl"},{"key":"10.1016\/j.coi.2025.102658_bib32","doi-asserted-by":"crossref","unstructured":"Joshi P., Dhaneshwar S.S. : An Update on Disease Modifying Antirheumatic Drugs. Inflamm Allergy - Drug Targets Discontin. 13(4):249\u2013261.","DOI":"10.2174\/187152811304140915152102"},{"key":"10.1016\/j.coi.2025.102658_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed Pharm"},{"key":"10.1016\/j.coi.2025.102658_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib36","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"10.1016\/j.coi.2025.102658_bib37","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102658_bib38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib39","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","article-title":"Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial","volume":"5","author":"Koehm","year":"2023","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3899\/jrheum.200124","article-title":"Methotrexate in psoriasis and psoriatic arthritis","volume":"96","author":"Coates","year":"2020","journal-title":"J Rheuma Suppl"},{"key":"10.1016\/j.coi.2025.102658_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib42","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.coi.2025.102658_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF01296156","article-title":"Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid","volume":"32","author":"Nielsen","year":"1987","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coi.2025.102658_bib47","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial","volume":"22","author":"Gupta","year":"1995","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib48","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","article-title":"Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study","volume":"35","author":"Combe","year":"1996","journal-title":"Br J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/rheumatology\/32.10.923","article-title":"Sulphasalazine in the management of psoriatic arthritis","volume":"32","author":"Fraser","year":"1993","journal-title":"Br J Rheuma"},{"issue":"5","key":"10.1016\/j.coi.2025.102658_bib50","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib51","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","article-title":"Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A department of veterans affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib53","first-page":"S101","article-title":"Cyclosporine in psoriatic arthropathy","volume":"33","author":"Soriano","year":"2015","journal-title":"Clin Exp Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis","volume":"64","author":"Fraser","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib55","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2133.1996.tb03885.x","article-title":"Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study","volume":"135","author":"Mahrle","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib57","first-page":"116","article-title":"A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis","volume":"15","author":"Levy","year":"1972","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib58","first-page":"160","article-title":"The long-term use of azathioprine in patients with psoriatic arthritis","volume":"7","author":"Lee","year":"2001","journal-title":"J Clin Rheuma Pr Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.coi.2025.102658_bib59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ijd.12231","article-title":"Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria?","volume":"53","author":"Gravani","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib60","first-page":"1724","article-title":"Chloroquine therapy in psoriatic arthritis","volume":"19","author":"Gladman","year":"1992","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coi.2025.102658_sbref61","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib63","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/03009742.2013.834964","article-title":"Etanercept decreases synovial expression of tumour necrosis factor-\u03b1 and lymphotoxin-\u03b1 in rheumatoid arthritis","volume":"43","author":"Nereg\u00e5rd","year":"2014","journal-title":"Scand J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib65","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib66","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib67","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib68","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib69","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib70","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib71","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3899\/jrheum.110242","article-title":"Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial","volume":"38","author":"Karanikolas","year":"2011","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib74","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib75","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102658_bib76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102658_bib77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102658_sbref77","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216658","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","volume":"81","author":"Raychaudhuri","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.coi.2025.102658_sbref79","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib81","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib83","first-page":"S136","volume":"65","author":"Gottleib","year":"2013","journal-title":"Arthritis Rheummatol"},{"key":"10.1016\/j.coi.2025.102658_bib84","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102658_bib85","series-title":"StatPearls [Internet]","article-title":"Brodalumab","author":"Golbari","year":"2024"},{"key":"10.1016\/j.coi.2025.102658_bib86","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib89","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coi.2025.102658_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.coi.2025.102658_bib91","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.coi.2025.102658_sbref91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102658_bib93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102658_bib94","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cellimm.2018.09.001","article-title":"IL-17 and limits of success","volume":"339","author":"Omidian","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib95","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2024-eular.1295","article-title":"OP0195 efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting NANOBODY\u00ae, in patients with active psoriatic aRTHRITIS (PsA): results from the Global, Randomized, Double-blind, Placebo-controlled Phase 2 Argo Trial","volume":"83","author":"Mc\u2009Innes","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib96","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheuma Hoboken NJ"},{"key":"10.1016\/j.coi.2025.102658_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003279","article-title":"The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials","volume":"9","author":"Denis","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102658_bib98","unstructured":"Study Details | Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03598751\u3009."},{"issue":"Suppl 10","key":"10.1016\/j.coi.2025.102658_bib99","article-title":"Regulatory role of IL-23 and its receptor system in spondyloarthritis and its therapeutic relevance in anti-IL-17 failure patients [abstract]","volume":"71","author":"Raychaudhuri","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102658_bib100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib101","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coi.2025.102658_bib102","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coi.2025.102658_bib103","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib106","unstructured":"Study Details | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04314544\u3009."},{"key":"10.1016\/j.coi.2025.102658_sbref104","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-silent, anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3899\/jrheum.120257","article-title":"The inhibitor of costimulation of T cells: abatacept","volume":"89","author":"Iannone","year":"2012","journal-title":"J Rheuma Suppl"},{"key":"10.1016\/j.coi.2025.102658_bib109","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib110","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2025.102658_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT Kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib113","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib114","first-page":"108","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn\u2019s disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.coi.2025.102658_bib115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102658_bib117","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib118","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib119","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib120","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib121","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coi.2025.102658_bib122","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib123","unstructured":"Study Details | To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT04957550\u3009."},{"key":"10.1016\/j.coi.2025.102658_bib124","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03963401\u3009."},{"key":"10.1016\/j.coi.2025.102658_bib125","unstructured":"Study Details | A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05153148\u3009."},{"key":"10.1016\/j.coi.2025.102658_bib126","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102658_bib128","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib129","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheuma Hoboken NJ"},{"key":"10.1016\/j.coi.2025.102658_sbref124","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102658_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102601","article-title":"Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis","volume":"95","author":"Raychaudhuri","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052638","article-title":"Inhibition of phosphodiesterase-4 in psoriatic arthritis and inflammatory bowel diseases","volume":"22","author":"Picchianti-Diamanti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102658_bib133","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib134","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib135","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102658_bib136","article-title":"Apremilast in the treatment of DMARD na\u00efve psoriatic arthritis patients: results of a phase 3 randomized controlled trial (PALACE 4) [abstract]","volume":"65","author":"Wells","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib137","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coi.2025.102658_bib138","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-014-0469-1","article-title":"Immune checkpoint receptors in regulating immune reactivity in rheumatic disease","volume":"16","author":"Ceeraz","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 10","key":"10.1016\/j.coi.2025.102658_bib139","article-title":"Efficacy and safety of neihulizumab (AbGn-168H) in patients with active psoriatic arthritis: 24-week results from a phase II open label study [abstract]","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102658_bib140","unstructured":"Clemetson K., Clemetson J.P.: Selectin Glycoprotein Ligand 1 - An Overview | ScienceDirect Topics. In [cited 2024 Sep 10]. Available from: \u3008https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/p-selectin-glycoprotein-ligand-1\u3009."},{"key":"10.1016\/j.coi.2025.102658_bib141","unstructured":"Study Details | A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis | ClinicalTrials.gov [Internet]. [cited 2024 Jul 21]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02267642\u3009."},{"key":"10.1016\/j.coi.2025.102658_sbref134","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102641","article-title":"Checkpoint agonists - immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis","volume":"96","author":"Baroz","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02786","article-title":"Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target","volume":"9","author":"Buerger","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib144","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.30278","article-title":"Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent","volume":"63","author":"Saxena","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib145","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1002\/art.30564","article-title":"Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis","volume":"63","author":"Raychaudhuri","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102658_bib146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cyto.2015.12.020","article-title":"IL-9, a local growth factor for synovial T cells in inflammatory arthritis","volume":"79","author":"Kundu-Raychaudhuri","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.coi.2025.102658_bib147","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2012.06.316","article-title":"IL-22 induced cell proliferation is regulated by PI3K\/Akt\/mTOR signaling cascade","volume":"60","author":"Mitra","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.coi.2025.102658_bib148","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/bjd.12271","article-title":"Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin","volume":"169","author":"Buerger","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib149","unstructured":"Wei KC, Lai PC: Combination of Everolimus and Tacrolimus: A Potentially Effective Regimen for Recalcitrant Psoriasis. Dermatol Ther - Wiley Online Libr [Internet]. 2015 [cited 2024 Sep 11]; Available from: \u3008https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/dth.12176\u3009."},{"key":"10.1016\/j.coi.2025.102658_bib150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-5154.123499","article-title":"mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target","volume":"59","author":"Raychaudhuri","year":"2014","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib151","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib152","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2014.07.003","article-title":"Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis \u2013 Xenograft model","volume":"55","author":"Kundu-Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102658_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180762","article-title":"Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial","volume":"12","author":"Tarcha","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.coi.2025.102658_bib154","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","article-title":"Ion channels in innate and adaptive immunity","volume":"33","author":"Feske","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib155","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/jcp.25356","article-title":"KCa3.1\u2212\/\u2212 mice do not develop CIA: regulatory role for KCa3.1 in autoimmune arthritis","volume":"231","author":"Raychaudhuri","year":"2016","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.coi.2025.102658_bib156","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.coi.2025.102658_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188391","article-title":"Pharmacological inhibition of ROR\u03b3t suppresses the Th17 pathway and alleviates arthritis in vivo","volume":"12","author":"Guendisch","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102658_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","article-title":"ROR\u03b3t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345","volume":"27","author":"Gege","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.coi.2025.102658_sbref150","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102602","article-title":"Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease","volume":"95","author":"Chakraborty","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102658_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102658_bib162","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/bjd\/ljad473","article-title":"Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis","volume":"190","author":"Gu\u00e9nin","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib163","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40257-022-00703-1","article-title":"Combination therapy with apremilast and biologics for psoriasis: a systematic review","volume":"23","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib164","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102658_bib165","doi-asserted-by":"crossref","DOI":"10.2196\/39972","article-title":"Machine learning approaches for predicting psoriatic arthritis risk using electronic medical records: population-based study","volume":"25","author":"Lee","year":"2023","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.coi.2025.102658_sbref157","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100207","article-title":"Evaluation of a machine learning tool for the early identification of patients with undiagnosed psoriatic arthritis \u2013 A retrospective population-based study","volume":"7","author":"Shapiro","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.coi.2025.102658_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004273","article-title":"Deep learning-based classification of erosion, synovitis and osteitis in hand MRI of patients with inflammatory arthritis","volume":"10","author":"Schlereth","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2025.102658_bib168","first-page":"114","article-title":"Artificial intelligence and prediction of response to biologics in psoriatic disease using immunophenotype data: a mini review","volume":"26","author":"Tsiogkas","year":"2024","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.coi.2025.102658_bib169","first-page":"2315","article-title":"Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations","volume":"41","author":"Ogdie","year":"2014","journal-title":"Rheumatol"},{"key":"10.1016\/j.coi.2025.102658_bib170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.111244","article-title":"Comorbidities of psoriatic arthritis \u2013 metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting","volume":"39","author":"Raychaudhuri","year":"2012","journal-title":"J Rheuma"},{"key":"10.1016\/j.coi.2025.102658_bib171","series-title":"Psoriasis and Psoriatic Arthritis","article-title":"Concept of total care: multidisciplinary approach for the management of psoriatic disease","author":"Raychaudhuri","year":"2017"},{"key":"10.1016\/j.coi.2025.102658_bib172","first-page":"35","article-title":"Concept of total care: a third dimension in the treatment of psoriasis","volume":"59","author":"Farber","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.coi.2025.102658_sbref164","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/met.2009.0124","article-title":"Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis","volume":"8","author":"Raychaudhuri","year":"2010","journal-title":"Metab Syndr Relat Disord"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:38:31Z","timestamp":1775032711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":173,"alternative-id":["S0952791525001347"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102658","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in treatment of psoriatic arthritis: current guidelines and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102658"}}